Sigma-Aldrich and Oxford BioMedica Pursue Protection of RNAi-Related Intellectual Property; File Suit Against Open Biosystems
Sigma-Aldrich and Oxford BioMedica have announced that they have filed a lawsuit against Open Biosystems, Inc. for infringement of key patents that cover key lentiviral-based systems for delivery of foreign DNA to a broad array of mammalian cells. The complaint, which was filed in U.S. District Court Eastern District of Missouri, alleges that Open Biosystems is infringing U.S. Patent Nos. 6924123 and 7056699. Rights to the patents, both entitled Lentiviral LTR Deleted Vector, were exclusively licensed for research use to Sigma-Aldrich by Oxford BioMedica in October 2005.
The suit states that, among other products, Open Biosystems' Lentiviral shRNAmir Library is marketed and sold to researchers and research institutions for incorporation into viral particles that infringe one or more claims of the patents.
Sigma-Aldrich has invested in its RNAi program through significant intellectual property and licensing activities. The lawsuit filed against Open Biosystems is a result of Sigma-Aldrich's desire to actively protect its intellectual property in this field.
Other news from the department politics & laws

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.